ethyl 3-iodocinnamate | 81069-39-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: ethyl 3-iodocinnamate
• 英文别名: (E)-ethyl 3-(3-iodophenyl)acrylate；ethyl (E)-3-(3-iodophenyl)acrylate；3-iodo-trans-cinnamic acid ethyl ester；3-Jod-trans-zimtsaeure-aethylester；ethyl (2E)-3-(3-iodophenyl)acrylate；ethyl (E)-3-(3-iodophenyl)prop-2-enoate
• CAS: 81069-39-8
• 化学式: C₁₁H₁₁IO₂
• 分子量: 302.112
• InChiKey: YCISVIBSKPOXRF-VOTSOKGWSA-N

物化性质

• 沸点：
  350.0±25.0 °C(Predicted)
• 密度：
  1.598±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  14
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  ethyl 3-iodocinnamate 在 二异丁基氢化铝 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 0.5h， 生成 (E)-3-(3-iodophenyl)prop-2-en-1-ol
  参考文献：
  名称：

  Protein-tyrosine phosphatase inhibitors and uses thereof

  摘要：

  本发明涉及式(I)的化合物，或其药用适宜盐或前药，用于选择性抑制蛋白酪氨酸磷酸酶-1B（PTP1B），并且用于治疗由过度表达或改变的蛋白酪氨酸磷酸酶1B引起的疾病。

  公开号：

  US20040214870A1
• 作为产物：
  描述：

  3-(3-碘苯基)丙烯酸 在 硫酸 作用下， 生成 ethyl 3-iodocinnamate
  参考文献：
  名称：

  Clark; Moore; McArthur, Transactions of the Royal Society of Canada, 1934, vol. <3> 28 III, p. 97

  摘要：

  DOI：

文献信息

• [EN] METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B<br/>[FR] PROCEDES PERMETTANT DE TRAITER DES TROUBLES SENSIBLES AU RETINOIDE AU MOYEN D'INHIBITEURS SELECTIFS DE CYP26A ET DE CYP26B
  申请人：ALLERGAN INC

  公开号：WO2005058301A1

  公开（公告）日：2005-06-30

  The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

  本发明提供了一种治疗患有视黄酸反应性障碍的个体的方法。在一个实施例中，一种方法包括向个体施用有效量的选择性CYP26B抑制剂，所述选择性CYP26B抑制剂相对于CYP26A至少具有10倍的选择性。在另一个实施例中，一种方法包括向个体施用有效量的选择性CYP26A抑制剂，所述选择性CYP26A抑制剂的化学公式如说明书所述。本发明还提供了用于识别选择性CYP26A抑制剂或选择性CYP26B抑制剂的筛选方法。
• Palladium Supported on a Polyionic Resin as an Efficient, Ligand-Free, and Recyclable Catalyst for Heck, Suzuki-Miyaura, and Sonogashira Reactions
  作者：Basudeb Basu、Fredrik Almqvist、Sajal Das、Pralay Das、Bablee Mandal、Dipanjan Banerjee

  DOI：10.1055/s-0028-1088003

  日期：2009.4

  could be soaked with palladium(0) from palladium salts, the formate counteranion being the reducing source. The resulting Amberlite resin formate supported with palladium(0), ARF-Pd, showed excellent catalytic activity in Heck, Suzuki­-Miyaura, and Sonogashira couplings with a range of substrates. The catalyst may be recovered easily and quantitatively without leaching and recycled; it was tested for

  可以通过用甲酸水溶液简单漂洗而得自市售Amberlite树脂氯化物的聚离子Amberlite树脂甲酸盐（ARF）可以用钯盐中的钯（0）浸泡，甲酸的抗衡阴离子是还原性来源。负载有钯（0），ARF-Pd的所得Amberlite树脂甲酸酯在Heck，Suzuki-Miyaura和Sonogashira偶联剂中与多种底物均表现出出色的催化活性。该催化剂可以容易地定量回收而无需浸出和再循环。对它进行了五次运行测试，没有任何明显的活性损失。 Amberlite树脂-CC偶联-非均相催化-钯
• Catalyst containing covalently bonded formate groups and Pd(0) and process for its obtention
  申请人：Almquest AB

  公开号：EP1994983A1

  公开（公告）日：2008-11-26

  1. A method of producing a heterogeneous catalyst suitable for catalyzing Heck, Suzuki-Miyaura and Buchwald-Hartwig reactions, comprising the steps of: a) providing a porous carrier, said porous carrier consisting of a core and a plurality of ion exchange groups covalently bonded to the surface of said core, where at least 90 % of the ions bound to said carrier are formate ions; b) providing a palladium (II) salt; c) suspending said carrier in an organic solvent thereby obtaining a suspension; d) adding said palladium salt to said suspension and allowing the resulting mixture to react at a temperature within the range of 30 - 70 °C until said carrier has turned black; e) washing said carrier in water; and f) drying said carrier under vacuum; characterised in that the resulting carrier subsequently is resuspended in dimethyl formamide and heated under inert atmosphere to at least 90 °C for 2 hours followed by washing with a polar solvent and drying. The invention also relates to a catalyst produced by the method and to processes where the catalyst is used for catalysing Heck, Suzuki-Miyaura, and Buchwald-Hartwig reactions.

  一种制备适用于催化Heck、Suzuki-Miyaura和Buchwald-Hartwig反应的非均相催化剂的方法，包括以下步骤： a）提供多孔载体，该多孔载体由核心和多个离子交换基团共价键合到核心表面组成，其中至少90％的离子结合到该载体上为甲酸根离子； b）提供钯（II）盐； c）将该载体悬浮在有机溶剂中，从而获得悬浮液； d）将该钯盐加入该悬浮液中，并允许所得混合物在30-70℃的温度范围内反应，直到该载体变黑； e）用水洗涤该载体； f）在真空下干燥该载体； 其特征在于，随后所得的载体在惰性气氛下在二甲基甲酰胺中重悬并加热至至少90℃，持续2小时，然后用极性溶剂洗涤并干燥。 该发明还涉及由该方法制备的催化剂以及使用该催化剂催化Heck、Suzuki-Miyaura和Buchwald-Hartwig反应的过程。
• Compounds having selective cytochrome P450RAI-1 or selective cytochrome P450RAI-2 inhibitory activity and methods of obtaining the same
  申请人：Vasudevan Jayasree

  公开号：US20050176689A1

  公开（公告）日：2005-08-11

  Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.

  本说明书提供的1至17式化合物可以特异性地抑制细胞色素P450RAI-1酶或细胞色素P450RAI-2酶。
• Methods for treating retinoid responsive disorders using selective inhibitors of CYP26A and CYP26B
  申请人：Vasudevan Jayasree

  公开号：US20050187298A1

  公开（公告）日：2005-08-25

  The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

  本发明提供了治疗具有视黄醇响应性疾病的个体的方法。在一种实施方式中，该方法涉及向个体施用有效量的选择性CYP26B抑制剂，该选择性CYP26B抑制剂相对于CYP26A具有至少10倍的选择性。在另一种实施方式中，该方法涉及向个体施用有效量的选择性CYP26A抑制剂，该选择性CYP26A抑制剂具有在规范中列出的化学式。本发明还提供了筛选方法，用于识别选择性CYP26A抑制剂或选择性CYP26B抑制剂。